Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898984 | 0.88 | SLC6A4 (0.37) | SLC22A6TDP1MAPTALDH1A1LMNA | |
| SCHEMBL11136905 | 0.88 | SIGMAR1 (0.42) | SLC22A6TDP1MAPTALDH1A1LMNA | |
| SCHEMBL10527389 | 0.88 | ECE1 (0.42) | SLC22A6LMNA | |
| SCHEMBL8999507 | 0.86 | GABRR1 (0.41) | LMNACACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL11134700 | 0.84 | GPR84 (0.42) | — | |
| SCHEMBL8061118 | 0.84 | TDP1 (0.43) | SLC22A6TDP1MAPTALDH1A1LMNA | |
| SCHEMBL20006676 | 0.84 | — | — | |
| SCHEMBL31688579 | 0.83 | CACNA2D1 (0.38) | ALDH1A1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL31688673 | 0.83 | CACNA2D1 (0.38) | ALDH1A1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL31513317 | 0.83 | CACNA2D1 (0.38) | ALDH1A1LMNACACNA2D1CACNB3CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348347-A1 | METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING | AIR COMPANY HOLDINGS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11052164-B2 | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10434200-B2 | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170333579-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348347-A1 | METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING | ADH1C, ADH1A, ADH5 | SLC22A6 4533/4885TDP1 2184/4885MAPT 1705/4885 |
| US-11052164-B2 | Compositions and associated methods for radioisotope-binding microparticles | CD47, CD68, MPI | SLC22A6 2420/4885TDP1 1488/4885MAPT 4174/4885 |
| US-20170333579-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | CD47, CD68, MPI | SLC22A6 2420/4885TDP1 1488/4885MAPT 4174/4885 |
| US-10434200-B2 | Compositions and associated methods for radioisotope-binding microparticles | CD47, CD68, MPI | SLC22A6 2420/4885TDP1 1488/4885MAPT 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.